The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia

NCT ID: NCT06458257

Last Updated: 2025-07-29

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-10-19
• Study Completion Date: 2028-12-31

Brief Summary

For newly diagnosed high-relapse-risk CEBPA mutant acute myeloid leukemia patients, we aim to perform allogeneic hematopoietic stem cell transplantation after patients finished one cycle of induction and two cycles of consolidation. To access whether the therapeutic regimen is effective for high-relapse-risk CEBPA mutant acute myeloid leukemia, the disease-free-survival (DFS), overall survival (OS), non-relapse-mortality of patients is evaluated.

Detailed Description

High-relapse-risk definition:

Participants with non-bZIP in-frame mutations, WT1 mutated status or CD7 negative status are considered of high-relapse-risk; The positive threshold for flow cytometry MRD was 0.0001%; The MRD threshold of molecular biology is the lowest value of the detection protocol of the center.

Conditions

Acute Myeloid Leukemia

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

HSCT-group

patients received allogeneic hematopoietic stem cell transplantation after consolidation treatment

Allogeneic Hematopoietic Stem Cell Transplantation

Intervention Type: PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Chemo-group

patients received chemotherapy after consolidation treatment

Chemotherapy

Intervention Type: DRUG

Chemotherapy

Interventions

Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation

Intervention Type: PROCEDURE

Chemotherapy

Chemotherapy

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients with confirmed CEBPA mutant AML. Diagnostic criteria include the presence of CEBPA mutant gene detected at the molecular level;

2. Patients with high-risk molecular markers or gene mutations, or complex karyotypes for disease recurrence, or flow cytometry/gene MRD positivity after two chemotherapy treatments; high-risk molecular markers or gene mutations include: CD7 positive, WT1 mutation, non-bzip-inframe CEBPA mutation; The positive threshold for flow cytometry MRD was 0.0001%; The MRD threshold of molecular biology is the lowest value of the detection protocol of the center.

3. Medical history and diagnosis of MICM, exclusion of MDS, transformation and treatment-related AML;

4. Age 18-65 years old (18 years old ≤Age< 65 years old);

5. Liver and kidney function: blood bilirubin ≤ 35 μmol/L, AST/ALT below 2 times the upper limit of normal, serum creatinine ≤ 150 μmol/L;

6. Normal cardiac function (EF≥50%, New York Cardiac Function Classification NYHA I/II);

7. Physical condition score 0-2 (ECOG score);

8. For patients with peripheral blood leukocytes < 50*109/L at the initial onset, no chemotherapy has been given except for hydroxyurea before the start of induction therapy;

9. For patients with peripheral blood leukocytes ≥ 50*109/L at the initial onset, cytarabine and hydroxyurea are allowed to be treated before the start of induction therapy;

10. Non-pregnant and lactating women;

11. For all women of childbearing age, a pregnancy test must be performed to measure hCG to rule out pregnancy;

12. Obtain informed consent signed by the patient or family member.

Exclusion Criteria

1. MDS-converted AML, treatment-related AML; mixed cell leukemia; AML patients with central nervous system infiltrates and extramedullary lesions at the time of onset;

2. Relapse patients;

3. Allergies or contraindications to any of the drugs involved in the protocol;

4. Liver and kidney function are obviously abnormal, exceeding the enrollment criteria;

5. Cardiac disease: including echocardiogram EF <50%, cardiac insufficiency (New York cardiac function classification NYHA: III/IV), pericardial effusion (CTCAE score >2) within six months after acute myocardial infarction, ECG QTc >470ms;

6. Lung diseases: pulmonary edema, pleural effusion (CTCAE score >2);

7. Suffering from malignant tumors of other organs at the same time;

8. Active patients with HAV, HBV, HCV and tuberculosis, HIV-positive patients;

9. Concomitant other hematologic diseases (including coagulation abnormalities unrelated to leukemia);

10. Inability to understand or follow the study protocol;

11. Those who participate in other clinical studies at the same time; Presence of any other condition that would preclude the conduct of the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ruijin Hospital

OTHER

Sponsor Role: lead

Responsible Party

Shen yang

Chief physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Ruijin Hospital Affiliated to Shanghai Jiaotong University School Of Medicine

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Facility Contacts

Jian Li, PhD

Role: primary

lj12116@rjh.com.cn

02164370045

Other Identifiers

CEBPA-AML01

Identifier Type: -

Identifier Source: org_study_id